Fintech PR
Decisions of UPM-Kymmene Corporation’s Annual General Meeting
HELSINKI, March 27, 2025 /PRNewswire/ — UPM-Kymmene Corporation Stock Exchange Release (Decisions of the Annual General Meeting) 27 March 2025 at 16:15 EET
Decisions of UPM-Kymmene Corporation’s Annual General Meeting
UPM-Kymmene Corporation’s Annual General Meeting was held today, 27 March 2025, in Helsinki.
The Annual General Meeting adopted the financial statements for 2024 and resolved on a dividend of EUR 1.50 per share for the financial period 2024. The dividend will be paid in two instalments. The Annual General Meeting adopted the Remuneration Report for Governing Bodies, resolved on the election of the auditor and the sustainability reporting assurer, authorised the Board of Directors to resolve on the issuance of new shares and special rights entitling to shares, the repurchase of the company’s own shares and charitable contributions, and resolved on the partial amendment of the Articles of Association.
Financial statements and dividend
The Annual General Meeting adopted the company’s financial statements and discharged the members of the Board of Directors and the President and CEO from liability for the financial period 1 January–31 December 2024. A dividend of EUR 1.50 per share is paid, as proposed by the Board of Directors. The dividend will be paid in two instalments. The first dividend instalment of EUR 0.75 per share will be paid to shareholders who are registered in the shareholders’ register of the company held by Euroclear Finland Ltd on the record date of the first dividend instalment, 31 March 2025. The payment date for the first dividend instalment is 8 April 2025. The second dividend instalment of EUR 0.75 per share will be paid to shareholders who are registered in the shareholders’ register of the company held by Euroclear Finland Ltd on the record date of the second dividend instalment, 31 October 2025. The payment date for the second dividend instalment is 7 November 2025.
Composition of the Board of Directors
The number of members of the Board of Directors was confirmed to be nine, and Henrik Ehrnrooth, Pia Aaltonen-Forsell, Jari Gustafsson, Piia-Noora Kauppi, Melanie Maas-Brunner, Topi Manner, Marjan Oudeman, Martin à Porta and Kim Wahl were re-elected to the Board of Directors. The directors’ term of office will end upon the closure of the next Annual General Meeting.
Remuneration Report
The Annual General Meeting adopted the Remuneration Report for Governing Bodies for the financial period 2024. The decision made by the Annual General Meeting is advisory.
Remuneration of the Board of Directors
It was resolved to increase the remuneration of the Chair and Deputy Chair of the Board of Directors so that the Chair of the Board of Directors will be paid an annual base fee of EUR 240,000 (previously EUR 231,000) and the Deputy Chair of the Board of Directors will be paid an annual base fee of EUR 150,000 (previously EUR 145,000). The remuneration of the other members of the Board of Directors will remain unchanged and they will be paid an annual base fee of EUR 120,000.
The Annual General Meeting resolved to pay the following annual remuneration to the members of the Board of Directors’ committees:
– Audit Committee: Chair EUR 50,000 (previously EUR 45,000) and members EUR 30,000 (previously EUR 25,000)
– Remuneration Committee: Chair EUR 27,500 and members EUR 10,000
– Nomination and Governance Committee: Chair EUR 20,000 and members EUR 10,000
The annual base fees are paid in Company shares and cash so that approximately 40 per cent will be payable in the Company shares to be purchased on the Board members’ behalf, and the rest in cash. The annual committee fees are paid in cash. If the term of a member of the Board terminates before the annual general meeting of 2026, the Board has a right to resolve upon potential reclaim of the annual fees as it deems fit.
The Company will pay any costs and transfer tax related to the purchase of the Company shares. Shares thus purchased may not be transferred within two years from the purchase date or until the director’s membership of the Board has ended, whichever occurs first.
In addition, the Annual General Meeting resolved that directors are compensated for actual travel and accommodation expenses related to Board and Committee work against invoice.
Election of an auditor for the financial period 2026 and an election of a sustainability reporting assurer for the financial period 2025 and 2026
Ernst & Young Oy, a firm of authorised public accountants, was elected as the company’s auditor for the financial period 2026. According to Ernst & Young Oy, Authorised Public Accountant (KHT) Heikki Ilkka will be the lead audit partner.
Ernst & Young Oy, a firm of authorised sustainability audit, was elected as the Company’s sustainability reporting assurer for the financial periods 2025 and 2026, with Authorised Sustainability Auditor (KRT) Heikki Ilkka as the principally responsible sustainability reporting assurer.
It was resolved that the remuneration of the auditor and the sustainability reporting assurer will be paid against invoices approved by the Board’s Audit Committee.
Authorisation to resolve on the issuance of shares and special rights entitling to shares
The Board of Directors was authorised to resolve on the issuance of new shares, transfer of treasury shares and issuance of special rights entitling to shares in proportion to the shareholders’ existing holdings in the Company, or in a directed share issue, deviating from the shareholder’s pre-emptive subscription right. The Board of Directors may also resolve on a share issue without payment to the Company itself. The aggregate maximum number of new shares that may be issued and treasury shares that may be transferred is 25,000,000 including also the number of shares that can be received on the basis of the special rights. The authorisation is valid for 18 months from the date of the Annual General Meeting.
Authorisation to resolve on the repurchase of the company’s own shares
The Board of Directors was authorised to resolve on the repurchase of a maximum of 50,000,000 of the company’s own shares using the company’s unrestricted shareholders’ equity as resolved by the Board. The price paid for the shares under the authorisation shall be based on the market price formed on the securities markets or a price otherwise formed in a competitive process. The shares may be repurchased either through an offer to all shareholders on equal terms or through other means and otherwise than in proportion to the existing shareholdings of the Company’s shareholders (directed repurchases). Shares may be repurchased to be cancelled, held to be reissued, transferred further or for other purposes resolved by the Board. The authorisation also includes the right to accept the Company’s own shares as a pledge. The Company may enter into derivative, share lending or other arrangements customary in capital market practice in connection with the repurchases. The authorisation is valid for 18 months from the date of the decision of the Annual General Meeting, and it revoked the authorisation granted by the previous Annual General Meeting to repurchase the company’s own shares to the extent that the Board of Directors has not already made decisions on repurchase based on the authorisation.
Partial amendment of the Articles of Association
The Annual General Meeting resolved to amend Article 10 of the Articles of Association (Notice of the General Meeting) so that it allows the General Meeting to be held entirely without a meeting venue as a so-called remote meeting. The legislative changes are based on the premise that shareholder rights shall not be compromised, and that all participating shareholders are able to exercise their full shareholder rights, including the right to vote and to ask questions in real time during the general meeting, irrespective of the chosen general meeting format.
The Annual General Meeting also resolved to add specifications concerning the sustainability reporting assurance and related technical amendments to Articles 8 (Auditor) and 11 (Annual General Meeting) of the Articles of Association.
Authorisation to resolve on donations for charitable purposes
The Board of Directors was authorised to resolve on contributions not exceeding a total of EUR 1,000,000 for charitable or corresponding purposes and to resolve on the recipients, purposes and other terms and conditions of the contributions. Contributions would be primarily granted under the Company’s Share and Care program whose focus areas are youth, education, and climate and biodiversity.
Minutes of the Annual General Meeting
The minutes of the Annual General Meeting will be available on the company’s website www.upm.com/agm2025 no later than 10 April 2025.
UPM, Media relations
Mon-Fri 9:00–16:00 EET
tel. +358 40 588 3284
media@upm.com
UPM
UPM is a material solutions company, renewing products and entire value chains with an extensive portfolio of renewable fibres, advanced materials, decarbonization solutions, and communication papers. Our performance in sustainability has been recognized by third parties, including EcoVadis and the Dow Jones Sustainability Indices. We operate globally and employ approximately 15,800 people worldwide, with annual sales of approximately €10.3 billion. Our shares are listed on Nasdaq Helsinki Ltd.
UPM – we renew the everyday
Read more: upm.com
Follow us on LinkedIn | Facebook | YouTube | Instagram | X | #UPM #materialsolutions #WeRenewTheEveryday
This information was brought to you by Cision http://news.cision.com
View original content:https://www.prnewswire.co.uk/news-releases/decisions-of-upm-kymmene-corporations-annual-general-meeting-302413374.html
Equity Insider News Commentary
Issued on behalf of Avant Technologies Inc.
VANCOUVER, BC, April 2, 2025 /PRNewswire/ — Equity Insider News Commentary – Artificial Intelligence (AI) is quickly becoming a major force in healthcare, as use of AI applications in medical fields is growing rapidly. Researchers at Dartmouth recently conducted the first clinical trial of a therapy chatbot powered by generative AI (genAI), and found that it resulted in significant improvements in participants’ symptoms. Cleveland Clinic and UAE-based G42 recently started collaborating on the advancement of even more AI in healthcare adoption, signalling an international push in this revolution. Because of this, the market is paying even more attention to developers in tech that are adding tools to the mix, with recent updates coming from Avant Technologies, Inc. (OTCQB: AVAI), Apple Inc. (NASDAQ: AAPL), Amazon.com, Inc. (NASDAQ: AMZN), Spectral AI, Inc. (NASDAQ: MDAI), and GE HealthCare Technologies Inc. (NASDAQ: GEHC).
The article continued: Billionaire Bill Gates recently predicted that he thinks AI will make medical advice free and commonplace, changing healthcare at a rapid pace along the way. Private company Layer Health just raised a fresh $21 million to take on Healthcare AI’s scalability challenges, with investment from Define Ventures, Flare Capital Partners, GV and MultiCare Capital Partners.
Avant Technologies Partner, Ainnova, to Sponsor and Present at 2025 Healthcare Innovation Summit in Mexico City
Avant Technologies, Inc. (OTCQB: AVAI), an emerging leader in AI-driven healthcare innovation, continues to build momentum in the AI-driven healthcare sector through its joint venture with Ainnova Tech, developers of the Vision AI platform. Today, the two companies announced that Ainnova will sponsor and present at the 2025 Mexico Healthcare Innovation Summit—an international event focused on digital transformation and diagnostics.
Ainnova’s CEO, Vinicio Vargas, will present on preventative healthcare powered by artificial intelligence, highlighting the practical impact of its Vision AI platform on early disease detection, which the company recently began designing the clinical trial protocols for ahead of a pre-submission meeting with the US Food and Drug Administration (FDA).
Vargas’s appearance at the event reinforces a consistent strategy for Avant and Ainnova: increasing visibility across key international markets ahead of major regulatory milestones to come.
It also follows Ainnova’s recent strategic alignment with Apollo Hospitals in Southeast Asia, where the Vision AI platform has been cleared for commercial deployment in Brazil, and clinical pilots are being prepared across the Americas.
As previously mentiond, Ainnova is being guided by global CRO Fortrea ahead of the important pre-submission meeting with the FDA. The goal is to seek 510(k) clearance for Vision AI in detecting diabetic retinopathy, a gateway to broader use across multiple chronic disease categories.
Avant and Ainnova jointly control Ai-nova Acquisition Corp. (AAC), which holds global licensing rights to the technology portfolio, including proprietary retinal cameras and algorithms validated on more than 2.3 million clinical data points.
Between FDA progress, high-profile alliances, and a growing international presence, Avant Technologies continues to carve out a niche in the convergence of AI, diagnostics, and preventative care. Investors looking for small-cap exposure to the healthcare AI revolution may want to keep AVAI on the radar as these developments unfold.
CONTINUED… Read this and more news for Avant Technologies at:
Apple Inc. (NASDAQ: AAPL) is reportedly working on an AI-driven health coach, under the codename Project Mulberry, as a revamped version of its Health app. For a while now, CEO Tim Cook has been promising that Apple’s long-term plans include a big push into more health-related technologies.
According to Bloomberg’s Mark Gurman, Apple could launch this as early as next year alongside a future iOS update. The service would give users tips on diet and exercise, using data from the Health app and Apple devices like the Apple Watch.
It’s still unclear whether this tool will act more like a real medical assistant or just a health and wellness coach. Gurman describes it as an “AI doctor service,” and the report says it’s being trained using real data from doctors and medical professionals. The service might be called Health Plus and could become a major part of Apple’s growing services business.
Amazon.com, Inc. (NASDAQ: AMZN) is pushing deeper into genAI itself, including testing health assistants with a chatbot tool focused on health and wellness, called Health AI, which can answer health and wellness questions, “provide common care options for health care needs,” and suggest products.
Already, Amazon’s shopping chatbot, Rufus, can suggest products like ice packs and ibuprofen. Where Health AI goes further will be in providing users with medical guidance and care tips, such as how to deal with flu or cold symptoms. Health AI also steers users to Amazon’s online pharmacy, along with clinical services offered by One Medical, the primary care provider it acquired for roughly $3.9 billion in 2022.
Spectral AI, Inc. (NASDAQ: MDAI) recently announced strong results from its Burn Validation Study, showing that its DeepView® System outperformed burn physicians in identifying non-healing tissue.
“We believe these are excellent results and we are thrilled with the analysis of our DeepView System in our Burn Validation Study,” said Dr J. Michael DiMaio, M.D. “The DeepView System exceeded our expectations in terms of predictive performance. Following the FDA’s review, if authorized by the agency, our hope is that this tool will provide an objective and immediate prediction of non-healing burn tissue to expedite patient care and reduce system costs across the board. We look forward to bringing this predictive diagnostic tool to the United States marketplace as soon as possible.”
The study, one of the largest of its kind in the U.S., demonstrated DeepView’s superior accuracy using AI and multispectral imaging to assess burn wounds on day one. The company plans to submit the data to the FDA by mid-2025, aiming for De Novo Clearance and rapid commercialization.
GE HealthCare Technologies Inc. (NASDAQ: GEHC) recently unveiled its new Revolution™ Vibe CT system, featuring advanced AI-powered cardiac imaging that delivers fast, accurate scans—even in complex cases like atrial fibrillation or heavy coronary calcification. The system’s Unlimited One-Beat Cardiac imaging and AI-driven workflow aim to improve diagnostic speed, patient comfort, and operational efficiency across healthcare facilities.
“Expanding access to CCTA is crucial for managing the rising prevalence of CVD, ensuring timely and accurate diagnoses for a larger patient population,” shares Jean-Luc Procaccini, President and CEO, Molecular Imaging and Computed Tomography, GE HealthCare. “Our introduction of Revolution Vibe underscores our commitment to this mission. The system is designed to encourage the broader adoption of and access to cardiac imaging, combining advanced technology with AI-powered solutions to deliver fast, accurate diagnoses and a more comfortable patient experience. It is designed to empower healthcare providers to offer the highest quality care, even in the most challenging cases.”
With FDA-recommended CCTA adoption on the rise and cardiac disease still the leading global cause of death, Revolution Vibe is designed to expand access to life-saving imaging and reduce reliance on invasive procedures.
CONTACT:
Equity Insider
info@equity-insider.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Logo – https://mma.prnewswire.com/media/2644233/5249022/Equity_Insider_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/fda-watch-the-quiet-gold-rush-in-ai-powered-medical-devices-302418684.html
Fintech PR
LITERA APPOINTS PRIYANKA SINGH AS CHIEF FINANCIAL OFFICER TO LEAD FINANCIAL STRATEGY AND GROWTH
— Singh Brings More Than Two Decades of Expertise in Global Financial Planning and Management —
CHICAGO, April 2, 2025 /PRNewswire/ — Litera, a global leader in legal technology solutions, is pleased to announce the appointment of Priyanka Singh as Chief Financial Officer. Priyanka brings extensive expertise to Litera, including financial leadership, transformation, M&A, and SaaS company management. She will report directly to Litera CEO Avaneesh Marwaha.
“At a critical time of rapid global growth for Litera and accelerated investment in innovation, robust financial leadership is essential to our agility and scale,” stated Avaneesh Marwaha, CEO of Litera. “Priyanka’s expertise in transformation will help ensure Litera remains responsive to this dynamic market as we continue to meet the evolving needs of legal professionals worldwide and exceed customer expectations.”
With more than two decades of expertise in financial strategy, operations, and compliance, coupled with a proven ability to lead cross-functional teams and collaborate with C-suite leadership, Singh’s comprehensive understanding of SaaS company management will enable her to streamline financial operations, ensuring that Litera can scale efficiently while maintaining robust fiscal health.
“I am thrilled to join Litera and contribute to its continued success and innovation. I believe that together we can achieve great milestones in the legal industry, advancing the positive impact our technology has on the way legal professionals work and driving transformative change,” expressed Singh.
Priyanka joins Litera from Togetherwork, where she held the position of Chief Financial Officer for over six years. Prior to joining Togetherwork, Priyanka held leadership roles at several public companies including Global Payments Inc., Heartland Payment Systems, GE Healthcare and USA Technologies, focusing on financial growth, strategic planning, and operational excellence.
Priyanka is a Certified Public Accountant (CPA) and a Chartered Accountant (CA) and holds a Bachelor of Commerce degree, specializing in Accounting, Finance and Taxation.
About Litera
For 30 years, Litera has led the legal technology revolution, combining decades of industry expertise with continuous innovation and a focus on AI-driven solutions. Litera empowers the world’s leading law firms with solutions for Legal Work, Firm Performance, and Firm Governance. Our intuitive, powerful tools transform how modern firms optimize workflows, collaborate, and leverage institutional knowledge. Serving more than 2.3 million legal professionals globally, Litera helps lawyers focus on their craft while making data-driven decisions, strengthening competitive advantage, and delivering enhanced client value. As pioneers in GenAI for legal technology, we continually evolve our solutions to shape the future of legal work. For more information about Litera, please visit www.litera.com or follow us on LinkedIn.
Photo: https://mma.prnewswire.com/media/2656576/Litera_Priyanka_Singh.jpg
Logo : https://mma.prnewswire.com/media/2656577/Litera_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/litera-appoints-priyanka-singh-as-chief-financial-officer-to-lead-financial-strategy-and-growth-302418673.html
MIAMI, April 2, 2025 /PRNewswire/ — As stated in the press release issued by TerraForm Power Parent, LLC on April 1, 2025, via GlobeNewswire:
“On January 20, 2025, a lawsuit filed in the United States District Court for the District of Maryland (Case Number: 8:18-cv-02523-PX) by Carlos Domenech against TerraForm Power Parent, LLC, formerly TerraForm Power, Inc. (“TERP”), and TerraForm Global Holdco LLC, formerly TerraForm Global, Inc. (“Global”), was resolved” in favor of Mr. Domenech. “Mr. Domenech was the CEO and President of TERP and Global and an Executive Vice President of SunEdison, the former sponsor and controlling shareholder of TERP and Global, until he was terminated by the TERP and Global Boards of Directors and SunEdison without cause on November 20, 2015. Brookfield Renewable Partners L.P., together with its institutional partners, acquired TERP and Global after Mr. Domenech’s termination”
“Mr. Domenech claimed in this lawsuit that he was unlawfully terminated for reporting to the Board of Directors of SunEdison his claims that SunEdison executives had made false statements about SunEdison’s liquidity to the investing public. Mr. Domenech alleged, among other things, false reporting by SunEdison executives of financial results and forecasts, and other misconduct. SunEdison filed for bankruptcy on April 21, 2016.”
“After nine years of litigation, the liability issues underlying Mr. Domenech’s allegations were the subject of a two-week bench trial conducted before the Honorable United States District Judge Paula Xinis in July and August 2024, who decided liability in favor of Mr. Domenech. The matter was resolved for $34,500,000.”
Carlos Domenech’s Comment on the Court Ruling
“This ruling underscores the gravity of the reasons behind my unlawful termination. It affirms my ethical course of action focused on protecting the interests of SunEdison, TERP, and Global shareholders while ensuring strict compliance with the law in matters of proper and transparent corporate governance—unlike the actions of other SunEdison executives and directors.”
“Core values and individual character shape a company’s culture. Integrity is the foundation, ensuring trust, transparency, and lasting success”.
Important Notice
This press release contains projections and pro forma financial information based upon assumptions that are inherently uncertain and unpredictable. Actual results may differ materially from those discussed in, or implied by, the statements in this press release. This press release and any projections or pro forma information contained herein represent only our management’s current estimates as of the date of this release and have not been subject to independent audit. We assume no duty to update the information contained in this press release. We make no representation or warranty as to the accuracy or completeness of the information contained in this press release. Unless otherwise specified, all greenhouse gas or carbon offsets or equivalencies are based on the United States Environmental Protection Agency Greenhouse Gas Equivalencies Calculator.
Logo – https://mma.prnewswire.com/media/1907378/5249062/Enfinity_Global_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/enfinity-global-statement-on-ceo-carlos-domenech-302418652.html
-
Fintech7 days agoFintech Pulse: Your Daily Industry Brief – March 26, 2025 | Featuring Chime, Klarna, Unlock Technologies, Fenergos
-
Fintech PR6 days agoPublic Sector Pension Investment Board announces new Chief Financial Officer and new Chief Risk Officer
-
Fintech PR5 days agoTransactions for persons discharging managerial responsibilities – CEO Jörg Brinkmann have purchased shares in H+H International A/S
-
Fintech5 days agoFintech Pulse: Your Daily Industry Brief – March 27, 2025 | Almond Fintech, Maplerad & More
-
Fintech PR5 days agoBybit Launches ‘Foolproof Fortune’ Event with 100,000 USDT Prize Pool and a Chance to Win a Luxury Watch
-
Fintech6 days agoFintech Pulse: Your Daily Industry Brief – March 27, 2025: Mercury, Jack Dorsey’s Startup, Grab Pay, Virginia, Straiker
-
Fintech PR4 days agoBRI Holds 2025 Annual General Meeting of Shareholders (AGMS), Distributes IDR 51.73 Trillion in Dividends and Prepares for IDR 3 Trillion Buyback
-
Fintech PR5 days agoAIM Congress 2025 to Spotlight AI’s Role in Business, Society, and Innovation with a Three-Day Conference